CRISPR/Cas9-mediated gene knock-out in zebrafish might be useful for determining the 23 pathogenicity of rare variants in patients with CCSD. 24 Translational Perspective: Whole-exome sequencing (WES) may be helpful in determining the 25 causes of cardiac conduction system disease (CCSD), however, the identification of pathogenic 26 variants remains a challenge. We performed WES of 23 probands diagnosed with early-onset CCSD, 27 and identified 12 pathogenic or likely pathogenic variants in 10 of these probands (43%) according to 28 the 2015 ACMG standards and guidelines. In this context, functional analyses of a cellular 29 electrophysiological study and CRISPR/Cas9-mediated gene knock-out in zebrafish might be useful 30 for determining the pathogenicity of rare variants, and SCN10A may be one of the major 31 development factors in CCSD. 32 33
Introduction 1
Bradyarrhythmia is a common clinical finding and can be usually due to a physiologic reaction, 2 pharmacotherapy, or advanced age. Patients with bradyarrhythmia may present with syncope, 3 symptoms of heart failure, and rarely sudden cardiac death. The cardiac conduction system 4 consists of the sinus node, atrio-ventricular node, and His-Purkinje system. Bradyarrhythmia can be 5 categorized on the level of disturbances in the hierarchy of this system and includes sinus node 6 dysfunction and atrioventricular conduction disturbances or blocks. 1 7 The pathophysiologic mechanisms underlying cardiac conduction-system disease (CCSD) 8 are divided into acquired or inherited causes. Several studies showed genetic variants associated 9 with CCSD linked to either structurally normal heart diseases (HCN4, CACNA1G, CACNA1D, SCN5A, 10 SCN1B, Cx40, KCNJ2, TRPM4, KCNK17, ANK2, CAV3, CASQ2, and RYR2 genes) or structural heart 11 diseases (MYH6, PRKAG2, Nkx2.5, Tbx5, LMNA, EMD, SGOL1, and LAMP-2 genes). 1-5 Thus, high-12
throughput sequencing (HTS) may be helpful in determining the causes of CCSD because of their 13 comprehensiveness. 6, 7 However, few studies exist whether whole exome sequencing is useful for 14 detecting causative variants in patients with early-onset CCSD. 15 Advancement of HTS has identified lots of putative variants associated with inherited cardiac 16 disease. However, determining true pathogenicity of targeted diseases is still a major challenge. 8 17 In 2015, the American College of Medical Genetics and Genomics (ACMG), the Association for 18 Molecular Pathology (AMP), and the College of American Pathologists reported updated standards 19 and guidelines for the classification of sequence variants using criteria informed by expert opinion 20 and empirical data. 9 This guideline consists of 28 criteria based on different sources of data 21 including population data, computational and predictive data, functional data, segregation data, de 22 novo data, and allelic data. Of these criteria, functional studies could be one of the powerful tools 23 in support for disease pathogenicity. 9 The gold standard for the functional analysis of ion-channel 24 variants is an electrophysiological measurement using a patch-clamp method in cell expression 25 systems 10 and a simulation study with mathematical models of human cardiomyocytes. In addition, 26 zebrafish is an emerging model for studying cardiac diseases, including cardiac arrhythmia. 11-16 27 Moreover, CRISPR/Cas9-mediated gene knock-out in zebrafish can facilitate high-throughput screens 28 for phenotypic effects with high levels of on-target efficiency and relatively off-target 29 modifications. 17, 18 However, in vivo zebrafish assay using CRISPR/Cas9 systems has not been fully 30 established for interpreting pathogenicity of human rare variants associated with CCSD. 31 Here, we assessed 23 probands diagnosed with early-onset CCSD with pacemaker 32 implantation (PMI) or a family history of PMI. We exome-sequenced for these patients to identify 33 putative variants that could cause a CCSD. Then, we performed functional studies to re-classify 34 guideline-based pathogenicity for these variants, using a patch-clamp method in heterologous 35 expression systems, a simulation study, and the combination of CRISPR/Cas9 systems with zebrafish. Methods section is available in the Online Supplementary Data. 3 4 
Study patients 5
The study conformed with the principles outlined in the Declaration of Helsinki and was approved by 6 the Ethics Committee for Medical Research at our institution. All study patients provided written 7 informed consent before registration. 8 The study patients were recruited from multiple hospitals in Japan. Early-onset CCSD was 9 defined as bradyarrhythmia occurring in individuals aged <65 years, who showed an atrioventricular 10 (AV) block and/or a sick sinus syndrome (SSS) with PMI or a family history of PMI as described in the 11 Online Supplementary Data. In addition, we used DNA-sequencing data of 102 control subjects 12 without electrocardiogram (ECG) abnormality. 13 14
DNA isolation and whole-exome DNA sequencing 15
WES was performed using the Illumina HiSeq platform (Illumina, San Diego, CA, USA) as described in 16 the Online Supplementary Data. After the standard quality control, we selected only the variants 17 that were absent in the in-house WES data from 102 control individuals without early-onset CCSD. 18 Of those, we extracted the variants in 117 candidate genes linked to arrhythmogenic disorders or 19 cardiomyopathy as a single gene disorder for further analyses ( Supplemental Table 1 ). 20 21
Pathogenicity of candidate variants 22
We interpreted the sequence variants using 2015 ACMG standards and guidelines, which provided 23 criteria for the classification of pathogenic or likely pathogenic variants. 9 Each pathogenic criterion 24 is weighted as very strong (PVS1), strong (PS1-4), moderate (PM1-6), or supporting (PP1-5). Rare 25 variants were defined as those with a minor allele frequency <0.5% in East Asians of the Human 26 Genetic Variation Database (HGVD) version 2.3 and the Genome Aggregation Database (gnomAD) 27 version 2.0.2. Variants that were absent from these databases were considered PM2. We 28 selected protein-truncating variants (PTVs) in known genes associated with CCSD (PVS1), or rare 29 missense variants registered as pathogenic or disease-causing mutations associated with CCSD in the 30 ClinVar and Human Gene Mutation Database (HGMD) (PP5) All variants were annotated by the 31 Variant Effect Predictor version 82 and referred following in silico damaging scores: MetaSVM for 32 missense variants; LOFTEE for PTVs; and CADD for all variants. 19 CADD score of 15 indicated that 33 the variant is predicted to be among the 15% most deleterious substitutions that can occur in the 34 human genome. When multiple lines of these in silico prediction algorithms supported a 35 deleterious effect on the gene, the supporting pathogenic evidence of PP3 was assigned. We 36 further sought to determine the relationship between the clinical phenotype (bradyarrhythmia) and 37 the genotype for probands and their relatives in whom a variant was identified (PP1 or PP4). These 38 segregation analyses were performed in the family members as much as possible. If the missense 39 variants are common causes of the disorder and the gene has very few benign variants, then a 40 missense variant in this gene can be supporting evidence for pathogenicity (PP2). Functional 41 studies used cellular electrophysiological analysis, mathematical modeling, and simulations, and 42 CRISPR/Cas9 mediated gene knock-out in zebrafish to confirm the pathogenicity of the detected 43 variants (PS3 or BS3). For a given variant, we selected the criteria based on the evidence observed 44 5 for the variant. The criteria are then combined according to the scoring rules to choose a 1 classification from the 5-tier system. 9 2 3
CRISPR-mediated deletions of the human LMNA ortholog, lmna, in zebrafish 4
All zebrafish experiments have been approved by Institutional Animal Care and Use Committee 5 (protocol# BWH 2016N000276), which is certified by the Association for Assessment and 6
Accreditation of Laboratory Animal Care. Zebrafish euthanasia was performed following NIH 7 (https://oacu.oir.nih.gov/animal-research-advisory-committee-guidelines) and American Veterinary 8
Medical Association guidelines using an overdose of Tricaine (M-222 or 3-aminobenzoic acid ethyl 9 ester) in combination with hypothermic shock. 10 The gene editing in zebrafish with CRISPR/Cas9 was conducted to evaluate detected PTV in 11 the LMNA gene from a patient with early-onset CCSD as described in the Online Supplementary 12
Data. 13
Cardiac phenotypes were scored at 48 and 72 hpf, and genomic DNA was prepared from 10 14 individuals for Sanger sequencing as described in the Online Supplementary Data. The heart rate 15 was visually counted at 48 hpf by using a stereomicroscope. Cardiac function was evaluated at 48 16 hpf by using video microscopy with an Axioplan (Zeiss) upright microscope. Voltage mapping was 17 recorded on isolated 72 hpf zebrafish hearts. 20 18
Mosaic founders (F0) were raised and were outcrossed to a wild-type line at the age of 3 19 months (Supplemental figure 1). Heterozygous F1 generation fishes with same lmna mutation were 20 incrossed, and cardiac phenotypes for F2 embryos were evaluated as stated above. Each F2 21 embryo was genotyped after evaluation of the cardiac phenotype to distinguish between 22 heterozygous and homozygous carriers. 23 24
Plasmid constructs and transfection of mammalian cell lines 25
Mutant cDNAs were constructed by an overlap extension strategy or using a QuikChange XL Site-26
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) as described in the Online 27 Supplementary Data. Mammalian cells were transfected with the cDNA encoding potassium or 28 sodium channels and green fluorescent protein (GFP) as described in the Online Supplementary 29 Data. Cells displaying green fluorescence 48-72 h after transfection were subjected to 30 electrophysiological analysis. 31 32
Electrophysiology and data analysis 33
Potassium or sodium currents were studied using the whole-cell patch clamp technique with an 34 amplifier, Axopatch-200B (Molecular Devices, Sunnyvale, CA, USA), at room temperature as 35 described in the Online Supplementary Data. 36 37
Mathematical modeling and simulations 38
With mathematical models of human ventricular myocytes 21 and rabbit peripheral sinoatrial node 39 (SAN) cells, 22 effects of the changes in kinetic behavior of IKr and INa on the mid-myocardial action 40 potential configuration of the ventricular myocyte model and pacemaker activity of the peripheral 41 SAN cell model connected to the atrial membrane model via the gap junction conductance were 42 evaluated. Dynamic behaviors of the model cell were determined by solving a system of nonlinear 43 ordinary differential equations numerically. Numerical integration was performed on Workstation 44 Dreifuss muscular dystrophy (EDMD) family including 16 carriers (7 men and 9 women) with EMD 23 p.W226X. EDMD caused by the EMD gene mutation is associated with X-linked recessive 24 inheritance. All of the 7 male carriers had cardiac involvement, and their first cardiac manifestation 25 occurred at age 10 to 37 years (mean age, 20.9 years) (PP1). 23 In patient 2, the segregation variant 26 was confirmed in the EMD gene (p. Q222X). Proband's parents did not have this variant which was 27 classified as de novo mutation (PS2). 28
Three patients harboring PTVs in the LMNA gene were diagnosed with CCSD at the age of 29 39, 23, and 44 years, respectively. Patient 3 with LMNA K114XfsX1 was a 55-year-old woman ( Table  30 3). Her ECG showed first-degree AV block at age 39 years and sinus arrest at age 41 years. She 31 had a family history of SCD and PMI. She received PMI at age 42 years and developed AF at 47 32 years. Echocardiogram showed low normal LV systolic function. Patient 4 with LMNA 1489-2A>G 33 was a 23-year-old man ( Table 3 ). His mother died suddenly due to ventricular fibrillation at the age 34 of 50 years. His ECG showed AF and complete AV block, and received ICD therapy. 35 Echocardiogram showed normal LV systolic function. Patient 5 with LMNA R321X was a 44-year-old 36 woman ( Table 3) . She had a family history of SCD and PMI. Her ECG showed paroxysmal AF at age 37 32 years and first-degree AV block at age 43 years. She received ICD therapy at the age of 44 years 38 old. Echocardiogram showed normal LV systolic function. 39
PTVs in the EMD and LMNA genes could be defined as pathogenic on the basis of "1 very 40 strong (PVS1) and 1 Moderate (PM2) and 1 supporting by the guideline (PP1, PP3, or PP5) ( Table 2) . 41 42
Functional studies of PTV in the LMNA gene using zebrafish 43
We studied the usefulness of in vivo zebrafish assay using CRISPR/Cas9-mediated gene knock-out for 44 8 interpreting PTVs associated with CCSD. We sought to confirm the functional effect of one of PTVs, 1 c. 339dupT, p. K114XfsX1 in the LMNA gene. The human LMNA homolog, lmna, in zebrafish is only 2 one copy, and the percentage of the orthologous sequence matching the human sequence is 63.13%. 3 The target site was selected around the equivalent lmna site of the human LMNA 4 c.339dupT ( Figure 1A ). Subsequently, sg RNA and Cas9 protein or only sg RNA was microinjected 5 into one-cell stage zebrafish embryos. At 48 hpf after the microinjection, the appearance of both 6 embryos looked similar (Supplemental Figure 2A ). Genomic DNA was prepared from 10 individuals, 7 and Sanger sequencing showed a variety of mutations in CRISPR/Cas9-injected embryos 8 (Supplemental Figure 2A) . At 48 hpf, the HR of zebrafish embryo was visually counted under 9 upright microscope. The mean HR of the CRISPR/Cas9-injected embryos significantly decreased 10 compared with those of CRISPR-only injected or non-injected embryos (Supplemental Figure 2B ). 11
Voltage mapping on isolated 72 hpf zebrafish hearts showed that the mean conduction velocities of 12 the ventricle (mm/s) were significantly decreased in the CRISPR/Cas9-injected embryos compared 13 with CRISPR-only injected embryos (8.0 ± 1.2 vs.16.8 ± 2.6; P<0.01) (Supplemental Figure 2C ). 14 We also evaluated F2 zebrafish embryos. Sequencing analysis of F1 fish after outcross 15 between mosaic founders (F0) and wild-type fishes showed various truncating indels. Of 10 16 genotyped F1 fish, 6 had heterozygous lmna c. 316_319 del GTGC, p. E108TfsX5, which caused a 17 premature stop codon (1 male and 5 females). Cardiac phenotypes for F2 embryos after incross 18 between these heterozygous fishes were evaluated. Subsequently, each F2 embryo was genotyped 19 after evaluation of the cardiac phenotype to distinguish between heterozygous and homozygous 20 carriers. The appearance of both embryos (lmna +/+ and lmna del/del ) looked similar ( Figure 1B) . 21
The mean HR of lmna del/del significantly decreased compared with those of lmna +/+ (Figure 2A ). The 22 evaluation of cardiac function using video microscopy showed that the mean stroke volume, mean 23 cardiac output, and the mean fractional area change of lmna del/del significantly increased compared 24 with those of lmna +/+ (Table 4 and Figure 2B ). Voltage mapping on isolated 72 hpf zebrafish hearts 25 showed that mean conduction velocities of both atrioventricular canal and ventricle were 26 significantly decreased in lmna del/del compared with lmna +/+ . In contrast, those of atrium were 27 comparable between these two groups ( Table 4 and Figure 2C and D). 28 29
Clinical characteristics of a patient harboring both two rare missense variants in KCNH2 and 30

SCN5A and functional properties of the variants 31
Furthermore, we sought to define the functional effect of 2 rare missense variants classified as 32 "uncertain significance" by the guideline in KCNH2 and SCN5A genes. 33 Patient 7 with SCN5A P1824A and KCNH2 R269W was a 47-year-old woman. 24 Her ECG 34 showed SA block, AV block, and marked QT prolongation (HR 56/min, QTc 0.56 s). Holter ECG 35 monitoring revealed a 4.5 seconds pause with transient loss of consciousness. She had a family 36 history of PMI and considered to be an indication for PMI. Echocardiogram showed normal LV 37 systolic function. 38 HEK293 cells were transiently transfected with vectors expressing wild-type or P1824A 39 cDNA and the human beta1 subunit cDNA in combination with a bicistronic plasmid encoding GFP. 40
Compared with the wild-type Nav1.5 channel, P1824A significantly reduced the peak sodium current 41 density. The maximum peak current density of P1824A was −846 ± 131 pA/pF, which was 42 significantly smaller than −1485 ± 186 pA/pF for wild-type (P<0.05) ( Figures 3A, 3C and Table 5 ). No 43 difference was found in persistent sodium current between wild-type (0.50% ± 0.07% of peak) and 44 9 P1824A (0.30% ± 0.07% of peak) ( Figure 3B ). The voltage dependence of steady-state activation of 1 P1824A was significantly shifted in depolarizing (+ 5.7 mV) directions ( Figure 3D and Table 5 ). No 2 significant difference was observed in the voltage dependence of steady-state fast inactivation 3 ( Figure 3D ). 4 Then, we transiently expressed Kv11.1 channels of wild-type, R269W, and wild-type + 5 R269W in cultured mammalian CHO-K1 cells for whole-cell voltage clamp measurements ( Figure 3E ). 6 Electrophysiological studies showed that the maximum tail current of R269W was 41.3 ± 7.4 pA/pF, 7 which was significantly smaller than 84.2 ± 11.2 pA/pF for wild-type (P<0.05) ( Figure 3F and Table 5 ). 8 The maximum tail current of wild-type + R269W was 75.7 ± 18.7 pA/pF, which was comparable to 9 that of wild-type alone. No significant difference in activation and deactivation kinetics was 10 observed among three channels (Figures 3G and H, Table 5 ). The steady-state inactivation was 11 shifted in its voltage dependence to a negative potential of −80.8 ± 8.6 mV for R269W and −63.0 ± 12 4.8 mV for wild-type + R269W compared with that of wild-type (−50.1 ± 4.5 mV) (R269W vs. wild-13 type, P<0.05) ( Figure 3G and Table 5 ). 14 Simulation study showed that the mutational changes in the conductance and 15 activation/deactivation/inactivation kinetics of IKr and INa prolonged the mid-myocardial action 16 potential duration by 58% in the patient model of human ventricular myocytes and led to the 17 formation of early afterdepolarizations when IKr was blocked by 7% ( Figures 4A and B ). The study 18 also showed that INa and IKr during spontaneous action potentials of the patient peripheral SAN 19 model were much smaller than those of the normal model ( Figure 4C ). Electrotonic modulations of 20 the atrial myocyte caused arrhythmic dynamics (bradyarrhythmia) and cessation of pacemaker 21 activity in the patient SAN model, but not in the normal one. 22 23
Clinical characteristics of a patient with rare PTV and missense variants in SCN10A gene, and 24
electrophysiological studies for these variants. 25 Finally, we found one PTV and 5 rare missense variants classified as "uncertain significance" by the 26 guideline in the SCN10A gene in 4 of 23 patients with CCSD (Table 3 ). Patient 6 with SCN10A 27 R1263X showed paroxysmal AF at age 49 years and had a sinus pause of 3.6 s following termination 28 of AF on his monitoring ECG at age 51 years. He received pacemaker therapy. He also had a rare 29 variant, KCNA5 T527M. We previously assessed the functional property of KCNA5 T527M 30 channel. 10 Cellular electrophysiological studies showed that the activating current density for 31 T527M was significantly larger than that for wild-type. The T527M mutant displayed a negative 32 voltage shift in the normalized activation curve. Patient 8 with SCN10A I1482V was diagnosed as 33 SSS, AV block, and AF at age 42 years. She received a pacemaker therapy at the age of 56 years old. 34 Patient 9 with SCN10A D1819Y and M1373R had AV block at age 31 years. She developed syncope 35 at age 36 years and received pacemaker therapy. Patient 10 with SCN10A F507L and G805S was a 36
17-year-old man who had SSS and received pacemaker therapy. Echocardiogram of these 4 37 patients showed normal LV systolic function. 38 ND7/23 cells were transiently transfected with vectors expressing wild-type, G805S, 39 R1263X, M1373R, I1482V, or D1819Y SCN10A cDNA in the plasmid encoding GFP. Figure 5A shows 40 representative current traces recorded for these wild-type and rare variant Nav 1.8 channels. 41
Neither R1263X nor M1373R generated sodium currents, whereas wild-type, G805S, I1482V, and 42 D1819Y generated sodium currents. Compared with the wild-type, G805S and D1819Y decreased 43 the peak sodium current density, and I1482V increased the current density. The maximum peak 44 10 current density of I1482V was −162.9 ± 30.3 pA/pF, which was significantly larger than −101.0 ± 8.9 1 pA/pF for wild-type (P<0.05) ( Figures 5A, B and Table 6 ). The voltage dependence of steady-state 2 activation of I1482V was significantly shifted by 8.9 mV in hyperpolarizing directions ( Figure 5C and 3 Table 6 ). G805S variant caused a significant depolarizing shift (+ 4.5 mV) in the voltage-dependence 4 of inactivation ( Figure 5D and Table 6 ). 5 6 
Classification of rare variants in consideration of functional studies 7
Above functional studies demonstrated that 8 rare variants in the KCNA5, KCNH2, SCN5A, SCN10A, 8 and LMNA genes could have damaging effects on each target gene (PS3) ( Table 2 ). Of those, 7 9 variants changed their clinical significance from "uncertain significance" to "likely pathogenic" when 10 added the functional study results: "1 strong (PS3) and 1 Moderate (PM2)" or "1 strong (PS3) and 2 11 supporting (PP3 and PP5) ( Table 2) . 12 13
Discussion 1
In the present study, we analyzed 23 patients with CCSD for rare variants in arrhythmia and/or 2 cardiomyopathy-related 117 genes using HTS. Since functional studies contributed greatly to the 3 determination of the precise pathogenicity of variants of unknown significance, we finally 4 determined 5 pathogenic variants in 5 patients and 7 likely pathogenic variants in 5 patients 5 according to 2015 ACMG standards and guidelines. 6 This study provided some interesting findings. First, we identified 2 PTVs in the EMD gene 7 and 3 PTVs in the LMNA gene as pathogenic. Also, we could confirm its pathogenicity by functional 8
properties of one PTV in the LMNA gene using the CRISPR/Cas9-mediated zebrafish. The EMD and 9
LMNA genes are known to be the disease-causing genes of EDMD with manifestation as high-grade 10 AV block. The former is associated with X-linked recessive inheritance and the latter with 11 autosomal dominant, autosomal recessive, and sporadic forms of EDMD. Both genes encode 12 nuclear envelope proteins. EDMD is a genetically heterogeneous disorder characterized by early 13 contractures, slowly progressive muscle wasting and weakness, and cardiomyopathy with conduction 14 block. Some patients present with conduction disturbances or atrial cardiomyopathy even when 15 skeletal myopathy is absent and are possible candidates for these mutations. In terms of 16 CRISPR/Cas9-mediated zebrafish analysis, it has been used as a useful in vivo model to assay the 17 pathogenicity of human variants in familial cardiovascular diseases. [25] [26] [27] Zebrafish has the 18 advantage of transparency, low cost, and the ability to manipulate their genome efficiently. 19
Zebrafish can gain a prominent role as the models of thousands of candidate disease-associated 20 genes and alleles. 28 The recent sequencing of zebrafish revealed that approximately 70% of human 21 genes had functional homologs in zebrafish. 28 We confirmed that the human LMNA homolog, 22 lmna, in zebrafish is only one copy, and the percentage of the orthologous sequence matching the 23 human sequence was 63.13%. Namely, human pathogenesis of CCSD with the LMNA gene 24 mutation could be modeled in zebrafish. 25 Second, we could determine the pathogenicity of 7 rare ion channel variants with 26 previously defined as "unknown significance" by two functional analyses, electrophysiological and 27 simulation studies. SCN5A P1824A and KCNH2 R269W were identified from the proband with SSS, 28 AV block, and QT prolongation. 24 Electrophysiological study demonstrated that both mutations 29 showed loss-of -function. A simulation study demonstrated that SCN5A P1824A might contribute to 30 sinus node dysfunction. The SCN5A gene encodes for the α-subunits of the voltage-gated Na + 31 channels (the Nav 1.5 channel), which is expressed in the conduction system and in the atrial regions 32 surrounding the SAN and the atrio-ventricular node. 29 In contrast, KCNH2 variant might contribute 33 to both sinus node dysfunction and QT prolongation as clinical phenotype expressions. The 34 simulation study was useful in explaining the role of each variant in multiple disorders. KCNA5 35 T527M was identified from the proband with SSS and AF. We previously reported that T527M 36 showed a gain-of-function effect with an enhanced steady-state activation, which could result in 37 susceptibility to AF and a sinus pause after the termination of AF. 10 However, this variant is present 38 at a relatively high frequency in East Asians which suggests either very low penetrance or only a 39 modifying effect. This proband also had likely pathogenic variant, SCN10A R1263X which showed 40 loss of function of Nav 1.8 channel and may be associated with proband's phenotype 41
Third, we determined 4 likely pathogenic variants in 4 of 23 (17%) CCSD patients in the 42 SCN10A gene. A cellular electrophysiological study demonstrated that three variants (G805S, 43 R1263X and M1373R) showed loss-of-function effects, and one variant (I1482V) showed gain-of-44 function effect. The voltage-gated sodium channel alpha subunit, Nav1.8 is encoded by the SCN10A 1 gene and is highly expressed in sensory neurons of dorsal root ganglia. Several genome-wide 2 association studies showed that SCN10A was associated with cardiac conduction. A recent review 3 showed how SCN10A variants promote dysfunctional conduction: the cardiomyocyte, enhancer, and 4 neuronal hypotheses. 30 CCSD caused by gain-of-function SCN10A rare variants may be explained 5 through the neuronal hypothesis. The neuronal hypothesis stipulates that SCN10A indirectly exerts 6 an effect on cardiac conduction through intracardiac neurons. SCN10A functions in cholinergic 7 neurons to exert negative chronotropic and dromotropic effects on sinus and AV nodal tissues and 8 modulates myocyte refractoriness. Gain-of-function SCN10A rare variants might cause vagus nerve 9 stimulation and cardiac conduction disturbance. In contrast, the mechanism of causing CCSD by 10 SCN10A loss-of-function rare variants is poorly understood. One possibility is that the enhancer 11 hypothesis may be associated with the onset of CCSD by these variants. The enhancer hypothesis 12 states that the cardiac enhancer located in Scn10a interacted with the promoter of Scn5a and was 13 essential for Scn5a expression in murine cardiac tissue. Further studies are needed to clarify the 14 mechanism by which loss-of-function SCN10A rare variants modulate cardiac conduction and lead to 15
This study has several limitations. First, only 117 genes linked to arrhythmogenic diseases 17 or cardiomyopathies were examined for rare variants associated with CCSD. Causative genes may 18 be included in the remaining genes other than these 117 genes. Second, of 13 probands with 19 family history, familial aggregation and segregation analysis were performed only for two families 20 with PTVs in the EMD gene. However, we evaluated pathogenicity of rare variants by functional 21 studies, including a patch-clamp method, a simulation study, and the CRISPR-mediated deletions of 22 the lmna in zebrafish. Third, approximately 30% of human genes did not have functional homologs 23 in zebrafish. Actually, we could not find a human EMD homolog in zebrafish and did not evaluate 24 the functional change of an EMD protein-truncating variant using zebrafish model. In addition, 25 functional properties of most missense variants in non-ion-channel genes were not evaluated in this 26 study. 27 28 29
Conclusions 30
Integrated HTS targeting 117 arrhythmia and cardiomyopathy-related genes with one-by-one various 31 functional studies, we identified 12 pathogenic or likely pathogenic variants in 10 of 23 CCSD 32 probands (43%): 5 probands harboring 5 pathogenic variants in genes encoding nuclear envelope 33 proteins; 5 probands had at least one likely pathogenic variant in genes encoding ion channels. 34 Notably, SCN10A may be one of the major development factors in CCSD. 35 214. 4 2.
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Figure 4 Computer simulation of the effects of modified kinetic behavior of Kv11.1 and Nav1.5 currents on electrophysiological properties of human ventricular myocytes (mid-myocardial cells) and the electrotonic effects of atrial myocytes on pacemaker activity of peripheral sinoatrial node (SAN) cells in a normal subject and a patient with modified
Likely pathogenic CCSD, cardiac conduction system diseases; SSS, sick sinus syndrome; AV block, atrioventricular block; FH, family history; PMI, pacemaker implantation; AF atrial fibrillation; LVEF, left ventricular ejection fraction; underlined and bold rare variants indicate pathogenic variants. Table 4 1 Table 5 Biophysical properties of wild-type and P1824A Nav1.5 channels, and wild-type and R269W Kv11.1 channels SF, Slope factor; * P<0.05 vs. wild-type Nav1. 
Impact of functional studies on interpretation of exome sequence variants in patients with earlyonset cardiac conduction-system diseases
Supplementary methods Study patients
The study conformed with the principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee for Medical Research at our institution. All study patients provided written informed consent before registration.
The study patients were recruited from multiple hospitals in Japan. Early-onset cardiac conduction system disease (CCSD) was defined as bradyarrhythmia occurring in individuals aged <65 years, who showed an atrioventricular (AV) block and/or a sick sinus syndrome (SSS) with pacemaker implantation (PMI) or a family history of PMI. AV block was defined as one of the following conditions: (1) every atrial impulse conducted to the ventricles, regular rate, but the PR interval exceeds 0.20 s (first-degree AV block), (2) blocking of some atrial impulses conducted to the ventricle at a time when physiological interference is not involved (second-degree AV block), or (3) no atrial activity is conducted to the ventricles (third-degree AV block). Sick sinus syndrome was defined as one of the following conditions: (1) persistent spontaneous sinus bradycardia not caused by drugs and inappropriate for the physiological circumstance, (2) sinus arrest or exit block, (3) combinations of sinoatrial (SA) and AV conduction disturbances, or (4) alternation of paroxysms of rapid regular or irregular atrial tachyarrhythmias and periods of slow atrial and ventricular rates. In addition, we used the DNA sequencing data of 102 control subjects without electrocardiogram abnormality.
DNA isolation and whole-exome DNA sequencing
Genomic DNA was extracted from peripheral blood leukocytes by using standard methods 1 . Five micrograms of genomic DNA of the patients was submitted to TAKARA BIO INC. (Kusatsu, Shiga, Japan) for whole-exome sequencing (WES). Exome capture was completed with SureSelect Human All Exon V5 + mtDNA (Agilent, Santa Clara, CA, USA). Exome sequencing was performed using the Illumina HiSeq platform (Illumina, San Diego, CA, USA). We used the Borrows-Wheeler Aligner Maximal Exact Match algorithm to align sequencing reads to human reference genome (build 37). We also used the Genome Analysis Toolkit (GATK ver.3.6) to perform reads' realignments and base quality recalibrations. We set the sensitivity of the Variant Quality Score Recalibration threshold as 99.6% and 95% for single nucleotide variants and insertions/deletions, respectively. After the above standard quality control, we selected only the variants that were absent in the in-house WES data from 102 control individuals without early-onset CCSD. Of those, we extracted the variants in 117 candidate genes linked to arrhythmogenic disorders or cardiomyopathy for further analyses (Supplemental Table 1 ).
Pathogenicity of candidate variants
We interpreted the sequence variants using 2015 ACMG standards and guidelines, which provided criteria for the classification of pathogenic or likely pathogenic variants. 2 
Each pathogenic criterion
Supplementary methods
Click here to access/download;Supplementary Material -Other;Supplementtal methods revised.docx is weighted as very strong (PVS1), strong (PS1-4), moderate (PM1-6), or supporting (PP1-5). Rare variants were defined as those with minor allele frequency <0.5% in East Asian at the Human Genetic Variation Database (HGVD) version 2.3 and the Genome Aggregation Database (gnomAD) version 2.0.2. Variants which were absent from these databases were considered as PM2. We selected protein-truncating variants (PTVs) in known genes associated with CCSD (PVS1), or rare missense variants registered as pathogenic or disease-causing mutation associated with CCSD in disease database including ClinVar and Human Gene Mutation Database (HGMD) (PP5). All variants were annotated by the Variant Effect Predictor version 82 and referred following in silico damaging scores: MetaSVM for missense variants; LOFTEE for PTVs; and CADD for all variants. 3 MetaSVM score incorporated 10 scores (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, GERP++, MutationTaster-2, Mutation Assessor, FATHMM, LRT, SiPhy, PhyloP) and the maximum frequency observed in 1000 genome populations. We used the MetaSVM scores from dbNSFP ver.2.9.1. 4 CADD score of 15 indicated that the variant is predicted to be among the 15% most deleterious substitutions that can occur in the human genome. When multiple lines of these in silico prediction algorithms supported a deleterious effect on the gene, the supporting pathogenic evidence of PP3 was assigned. We further sought to determine the relationship between the clinical phenotype (bradyarrhythmia) and the genotype for probands and their relatives in whom a variant was identified (PP1 or PP4). These segregation analyses were performed in the family members as much as possible. If the missense variants are common causes of the disorder and the gene also has very few benign variants, then a missense variant in this gene can be supporting evidence for pathogenicity (PP2). Functional studies were performed using cellular electrophysiological analysis, mathematical modeling, and simulations, and CRISPR/Cas9 mediated gene knock-out in zebrafish to confirm the pathogenicity of detected variants (PS3 or BS3). For a given variant, we selected the criteria based on the evidence observed for the variant. The criteria then are combined according to the scoring rules to choose a classification from the five-tier system 2 .
CRISPR-mediated deletions of the human LMNA ortholog, lmna, in zebrafish
All zebrafish experiments have been approved by Institutional Animal Care and Use Committee (protocol# BWH 2016N000276), which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care. Zebrafish euthanasia was performed following NIH (https://oacu.oir.nih.gov/animal-research-advisory-committee-guidelines) and American Veterinary Medical Association guidelines using an overdose of Tricaine (M-222 or 3-aminobenzoic acid ethyl ester) in combination with hypothermic shock. The gene editing in zebrafish with CRISPR/Cas9 was conducted to evaluate detected PTV in the LMNA gene from patients with early-onset CCSD. The target site of the human LMNA ortholog, lmna, in zebrafish was selected using a CHOPCHOP webtool, which ranks target sites based on potential off-target effects (5'-GGAGCTCAGCAAAGTGCGTG-3'). Single guide (sg) RNA was generated by in vitro transcription from oligonucleotide-based templates with a MEGAshortscript™ T7 Transcription Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). DNA double-strand breaks (DSBs) introduced by CRISPR at the target site can be repaired through error-prone nonhomologous end-joining (NHEJ) pathway. The DSB repair by NHEJ could generate indel mutations, which can cause frame shift and then abolish gene function if the mutations occur in an exon. Two microliters of sgRNA stock (400 ng/μl) was mixed with 2 μl of recombinant Cas9 protein (1 μg/μl) (PNA Bio, Newbury Park, CA, USA) and 2μl of water, then incubated on ice for 5 min to allow formation of the sgRNA/Cas9 complex. One nanoliter of the injection mix was injected intracellularly in one-cell stage zebrafish embryos by using glass needles and a micromanipulator. Zebrafish embryos were maintained in E3 water at 28°C.
Cardiac phenotypes were scored at 48 and 72 hpf, and genomic DNA was prepared from 10 individuals for Sanger sequencing. The heart rate was visually counted at 48 hpf by using a stereomicroscope. Cardiac function was evaluated at 48 hpf by using video microscopy with an Axioplan (Zeiss) upright microscope. 816 flames (magnification, 10×; frame rate, 250/s) were captured, and sequential still frames were analyzed by Image J. Voltage mapping was recorded on isolated 72 hpf zebrafish hearts 5 . Dissected hearts were stained with FluoVolt (Thermo Fisher Scientific Inc., Waltham, MA, USA) and immobilized with blebbistatin or Cytochalasin D (Sigma-Aldrich, St. Louis, MO, USA) for the measurement of action potentials. Fluorescence intensities were recorded with a high-speed charge coupled-device camera (RedShirtImaging, Decatur, GA, USA). Acquired fluorescence images were exported as tiff stacks and analyzed using Matlab software (Mathworks, Natick, MA, USA).
Mosaic founders (F0) were raised and outcrossed to a wild-type line at the age of 3 months. Sequencing analysis of F1 fish after outcross was performed at the age of 5 months, and various truncating indels of lmna gene were confirmed. Heterozygous F1 fishes with same lmna mutation were incrossed, and cardiac phenotypes for F2 embryos were evaluated as stated above. Each F2 embryo was genotyped after evaluation of the cardiac phenotype to distinguish between heterozygous and homozygous carriers.
Plasmid constructs and transfection of mammalian cell lines
The KCNH2 cDNA in the mammalian expression vector pSI, the SCN5A cDNA in the pCGI vector 6 , SCN1B cDNA in the IRGFP vector, and the SCN10A cDNA in the pIRES2-EGFP plasmid were kindly provided by Dr. Sabina Kupershmidt and Dr. Dan Roden (Vanderbilt University). Mutant cDNAs were constructed by an overlap extension strategy or using a QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). With regard to the study of Nav1.5 current, HEK293 cells were transiently transfected with wild-type SCN5A cDNA (0.5 μg), or mutant SCN5A cDNA (0.5 μg), using a FuGENE 6 Transfection Reagent (Roche Applied Science, Penzberg, Germany). Cells were cotransfected with the same amount of SCN1B cDNA in the IRGFP vector as each sodium channel cDNA. With regard to the studies of Kv11.1 current, CHO-K1 cells were transiently transfected with wild-type KCNH2 cDNA (0.5 μg) or mutant KCNH2 cDNA (0.5 μg), using a FuGENE 6 Transfection Reagent (Roche Applied Science, Penzberg, Germany). Cells were cotransfected with the same amount of green fluorescent protein (GFP) as each potassium channel cDNA. With regard to the study of Nav1.8 current, ND 7/23 cells were transiently transfected with 3 μg of the cDNA encoding human wild-type or variant Nav1.8, using an X-tremeGENE 9 DNA Transfection Reagent (Roche Applied Science, Penzberg, Germany). ND 7/23 cells were kindly provided by Dr. Naomasa Makita (Nagasaki University). Cells displaying green fluorescence 48-72 h after transfection were subjected to electrophysiological analysis.
Electrophysiology and data analysis
Potassium or sodium currents were studied using the whole-cell patch clamp technique with an amplifier, Axopatch-200B (Molecular Devices, Sunnyvale, CA), at room temperature (23°C-25°C for potassium currents and 20°C-22C for sodium currents). Electrode resistance ranged from 2 to 4 M and from 0.8 to 1.5 M for potassium and sodium channel recordings, respectively. The voltage clamp protocols are described in the Figures. Data were acquired using pCLAMP software (v. 9; Molecular Devices, Sunnyvale, CA, USA). Data acquisition and analysis were performed using a Digidata 1321 A/D converter and pCLAMP8.2 software (Molecular Devices, Sunnyvale, CA, USA). While recording potassium currents, the pipette solution (intracellular solution) contained 110 mM KCl, 5 mM K2ATP, 2 mM MgCl2, 10 mM HEPES, and 5 mM K4BAPTA at pH 7.2, and the bath solution contained 140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 1.0 mM MgCl2, 10 mM HEPES, and 10 mM glucose, adjusted to pH 7.4 with NaOH. While recording Nav1.5 currents, the pipette solution (intracellular solution) contained 10 mM NaF, 110 mM CsF, 20 mM CsCl, 10 mM EGTA, and 10 mM HEPES at pH 7.35 with CsOH. The bath solution contained 145 mM NaCl, 1.5 mM CaCl2, 4.5 mM KCl, 1 mM MgCl2, 10 mM HEPES, and 5 mM glucose, adjusted to pH 7.4 with CsOH.
While recording Nav1.8 currents, the pipette solution (intracellular solution) contained 10 mM NaF, 110 mM CsF, 20 mM CsCl, 5 mM EGTA, 10 mM HEPES, and 5 mM Mg2-ATP, with a pH of 7.3 adjusted with 4 CsOH. The bath solution contained 135 mM NaCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 20 mM TEA-Cl, 10 mM HEPES, and 10 mM glucose, with a pH of 7.4, adjusted with NaOH. Endogenous tetrodotoxin (TTX)-sensitive INa and L-and T-type calcium currents were eliminated with TTX 200 nM, nisoldipine 1 μM and NiCl2 200 μM, respectively.
The voltage dependence of potassium current activation was determined for each cell by fitting peak values of tail current (Itail) versus test potential to a Boltzmann function in the following form: Itail=Itail-max/｛1+ exp[(V1/2 − Vt) / k]｝, where Itail-max is peak Itail, Vt is the test potential, V1/2 is the voltage at which Itail is half of Itail-max, and k is the slope factor 7 . Steady-state inactivation of the potassium current was analyzed as previously described 8 . Briefly, the corrected steady-state inactivation curves were fitted with a Boltzmann function in the following form: I/(Ima − Imin) = 1/｛1+ exp[(Vt − V1/2) / k]｝ + Imin, where I is the amplitude of the inactivating current corrected for deactivation, Imax is the maximum of I, Imin is the minimum of I, Vt is the prepulse of test potential, V1/2 is the voltage at which I is half of Imax, and k is the slope factor. Deactivation rates of Kv11.1 channels were measured using a two-step voltage protocol and by fitting tail currents with two exponential functions 7 .
The parameters for voltage dependence of sodium current activation were estimated from the currentvoltage relationship based on the Boltzmann equation in the following form: I = Gmax × (V − Vrev) × (1 + exp[V − V1/2]/k) -1 , where I is the peak Na current during the test pulse potential V. The parameters estimated by the fitting are Gmax (maximum conductance), Vrev (reversal potential), and k (slope factor) 9 . Steady-state availability for fast inactivation was measured with a standard double-pulse protocol, and the data were fit with the Boltzmann equation in the following form: I/Imax = (1 + exp[(V − V1/2)/k]) -1 , where Imax is the maximum peak Na current, to determine the membrane potential for V1/2 and k 9 .
Mathematical modeling and simulations
With mathematical models of human ventricular myocytes 10 and rabbit peripheral sinoatrial node (SAN) cells 11 , the effects of the changes in kinetic behavior of IKr and INa on the mid-myocardial action potential configuration of the ventricular myocyte model and pacemaker activity of the peripheral SAN cell model connected to the atrial membrane model via the gap junction conductance were evaluated. Dynamic behaviors of the model cell were determined by solving a system of nonlinear ordinary differential equations numerically. Numerical integration was performed on Workstation HP xw9400 with MATLAB 7.5 (The MathWorks, Inc., Natick, MA, USA). The numerical algorithms available as a MATLAB ODE solver, ode15s (a variable time-step numerical differentiation approach selected for its suitability to stiff systems) were used.
Statistical analysis
Pooled electrophysiological data were expressed as mean±standard error. Two-tailed Student's ttest was used for single comparisons between two groups. One-way ANOVA, followed by a Bonferroni post hoc test, was used to analyze data with equal variance among three or more groups. A value of P<0.05 was considered statistically significant. Statistical analysis was performed using JMP Pro 11.0.0 (SAS Institute Inc., NC, USA) and Origin 2018 (OriginLab, Northampton, MA, USA). Table 1 CCSD candidate 117 genes linked to arrhythmogenic diseases or  cardiomyopathies  ABCC9  COL3A1  ILK  MAP2K1  PRKAG2  TBX5  ACTA2  CRYAB  JPH2  MAP2K2  PTPN11  TCAP  ACTC1  CSRP3  JUP  MOG1  RAF1  TGFB3  ACTN2  DES  KCNA5  MYBPC3  RBM20  TGFBR1  AKAP9  DMD  KCND3  MYH6  RYR2  TGFBR2  ANKB  DMPK  KCNE1  MYH7  SCN10A  TMEM43  ANKRD1  DSC2  KCNE2  MYH11  SCN1B  TMPO  BAG3  DSG2  KCNE3  MYL2  SCN2B  TNNC1  BRAF  DSP  KCNE5  MYL3  SCN3B  TNNI3  CACNA1C  EMD  KCNH2  MYLK  SCN4B  TNNT2  CACNA2D1  EYA4  KCNJ2  MYLK2  SCN5A  TPM1  CALM1  FBN1  KCNJ3  MYO6  SGCD  TRDN  CALM2  FBN2  KCNJ5  MYOZ2  SHOC2  TRPM4  CALM3  FXN  KCNJ8  MYPN  SLAMP  TTN  CALR3  GJA1  KCNN2  NEXN  SLC2A10  TTR  CASQ2  GJA5  KCNQ1  NKX2.5  SLC8A1  TXNRD2  CAV3  GLA  KRAS  NRAS  SMAD3  VCL  CBL  GPD1L  LAMP2  PDLIM3  SNTA1  CBS  HCN4  LDB3  PKP2  SOS1  CMK2D HRAS 
